* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Clinuvel Pharmaceuticals's PEG Ratio or its related term are showing as below:
FRA:UR9'
s PEG Ratio Range Over the Past 10 Years
Min: 0.72 Med: 1.21 Max: 1.98
Current: 0.83
During the past 13 years, Clinuvel Pharmaceuticals's highest PEG Ratio was 1.98. The lowest was 0.72. And the median was 1.21.
FRA:UR9's PEG Ratio is ranked better than 67.89% of 109
companies
in the Biotechnology industry
Industry Median: 1.58
vs FRA:UR9: 0.83
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Clinuvel Pharmaceuticals PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Clinuvel Pharmaceuticals's PEG Ratio
For the Biotechnology subindustry, Clinuvel Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinuvel Pharmaceuticals's PEG Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Clinuvel Pharmaceuticals's PEG Ratio falls into.
Clinuvel Pharmaceuticals PEG Ratio Calculation
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio.
The ratio we use is the 5-Year EBITDA growth rate.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Clinuvel Pharmaceuticals (FRA:UR9) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Clinuvel Pharmaceuticals PEG Ratio Related Terms
Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Clinuvel Pharmaceuticals (FRA:UR9) Business Description
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:UR9 has been successfully added to your 